Sanofi says Gaucher pill studies meet goals

PARIS Fri Feb 15, 2013 10:44pm IST

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013. REUTERS/Jacky Naegelen

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013.

Credit: Reuters/Jacky Naegelen

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly.

Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts.

Patients with Gaucher disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

The first study, presented at a medical congress on Friday, compared eliglustat with a placebo, while the second compared it with Cerezyme, an injectable treatment also sold by Sanofi.

Patients treated with the pill showed a "statistically significant improvement" in the size of their spleen - which typically swells as a result of Gaucher disease - without reporting serious side effects, Sanofi said.

Eliglustat also proved to be as good as Cerezyme at treating the symptoms of the disease, the drugmaker added.

Full data from the second trial will be presented at a medical meeting in the second half of 2013, Sanofi said in a statement.

A third late-stage study is currently testing whether the dosage for eliglustat could be reduced to once from twice daily.

In addition to Cerezyme, which for many years dominated the Gaucher market and was at one point the most expensive drug in the world, costing more than $200,000 a year, current treatments include Shire's Vpriv and Elelyso, sold by Pfizer.

(Reporting by Elena Berton; Editing by Christian Plumb and James Regan)

FILED UNDER:

Reuters Showcase

India Crush UAE

India Crush UAE

India cruise to easy win over UAE in Perth.  Read 

Budget 2015

Budget 2015

Full coverage of 2015/16 budget.  Full Coverage 

Sahara Saga

Sahara Saga

Some staff say Sahara has not paid salaries for months   Full Article 

Movie Review

Movie Review

"Dum Laga Ke Haisha" is rooted in reality, writes Shilpa Jamkhandikar.  Full Article | Related Story 

Nimoy Dies

Nimoy Dies

Leonard Nimoy, Star Trek's 'Mr. Spock,' dies at 83.  Full Article 

Gown Returned

Gown Returned

Lupita Nyong'o's $150,000 Oscar gown returned by thief via TMZ.  Full Article 

World Cup 2015

World Cup 2015

Full coverage of cricket world cup in Australia and New Zealand.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage